TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1455371

Group type: EXPERIMENTAL
Intervention: Hemosorption weekly for 3 weeks, followed by cyclophosphamide 1000 mg IV after the second procedure, then methotrexate 7.5 mg weekly.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methotrexate 7.5 mg weekly.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 200 mg IV twice a week for 6 times, then 200 mg weekly orally until a total dose of 2 g.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Azathioprine 100 mg daily.
Number of subjects: 32
Study: 3334188

Group type: EXPERIMENTAL
Intervention: Ranitidine at 300 mg daily for the control of symptoms of non-ulcer dyspepsia
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 29746903

Group type: EXPERIMENTAL
Intervention: famciclovir 500mg (one tablet) three times daily for 7 days
Number of subjects: 174

Group type: COMPARATOR
Intervention: acyclovir 800mg (two capsules) five times daily for 7 days
Number of subjects: 174
Study: 27354043

Group type: EXPERIMENTAL
Intervention: Long-acting nifedipine (10-60 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional treatments alone
Number of subjects: 100
Study: 24355438

Group type: EXPERIMENTAL
Intervention: Protein pulse feeding (PD), 72% of dietary protein consumed in one meal at noon, averaging 1.31 g/kg body weight daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Protein spread feeding (SD), dietary protein spread over four daily meals
Number of subjects: 66
Study: 23318621

Group type: EXPERIMENTAL
Intervention: Virtual‐Fracture‐Carving Simulator
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sawbones
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 21502597

Group type: COMPARATOR
Intervention: Huperzine A 200 μg BID
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Huperzine A 400 μg BID
Number of subjects: 210
Study: 19841339

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride, 2%, with 1:100 000 epinephrine (group 1)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Lidocaine, 2%, with 1:200 000 epinephrine (group 2)
Number of subjects: 140
Study: 16766774

Group type: EXPERIMENTAL
Intervention: Special nutritional supplement providing 90 mg isoflavones, 800 mg calcium, 400 IU vitamin D, 60 ug vitamin K and 31 g proteins per day.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual nutritional supplement provided by the Chilean Ministry of Health.
Number of subjects: 0
Study: 15120551

Group type: EXPERIMENTAL
Intervention: Symbol-string task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Developmental dyslexic readers
Number of subjects: 0
Study: 11115724

Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus-based quadrivalent vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9543218

Group type: EXPERIMENTAL
Intervention: 1000 mg of micronised flavonoid fraction for 2 months
Number of subjects: 895
Study: 8224273

Group type: EXPERIMENTAL
Intervention: Assisted hatching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 2871145

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 10
Study: 28580791

Group type: EXPERIMENTAL
Intervention: Arm accelerometer
Number of subjects: 82
Study: 26754933

Group type: EXPERIMENTAL
Intervention: Telehealth (TH) group
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard of Care (SOC) group
Number of subjects: 122
Study: 24997093

Group type: EXPERIMENTAL
Intervention: 4,000 SQ+
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 15,000 SQ+
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 22921297

Group type: EXPERIMENTAL
Intervention: Targeted voice hygiene (VH) program
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Voice hygiene (VH) program plus resonant voice training (VH+VT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 19734790

Group type: EXPERIMENTAL
Intervention: gabapentin 1200 mg + dexamethasone 8 mg + ketamine (0.15 mg kg(‐1)) + paracetamol 1 g + ketorolac 15 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo + paracetamol 1 g + ketorolac 15 mg
Number of subjects: 42
Study: 18364384

Group type: EXPERIMENTAL
Intervention: Diet and exercise (treatment group; n = 17)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No therapy (control group; n = 10)
Number of subjects: 27
Study: 15452357

Group type: EXPERIMENTAL
Intervention: Cream adjusted to pH 4.0
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cream adjusted to pH 7.5
Number of subjects: 0
Study: 12417880

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 150 microg twice daily, n = 20
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo, n = 20
Number of subjects: 62
Study: 10714780

Group type: EXPERIMENTAL
Intervention: Lateral buttress plate with anteromedial antiglide plate
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Dual buttress construct
Number of subjects: 1

Group type: COMPARATOR
Intervention: Lateral buttress plate alone
Number of subjects: 1
Study: 7532559

Group type: EXPERIMENTAL
Intervention: Methylene blue (2 mg/kg)
Number of subjects: 14
Study: 1774375

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 47
Study: 6123021

Group type: EXPERIMENTAL
Intervention: Synthetic methionyl human growth hormone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Pituitary human growth hormone
Number of subjects: 22
Study: 31477688

Group type: EXPERIMENTAL
Intervention: Functional polygenic risk scores (PRSs) created using gene set enrichment analysis applied to meta-GWAS data
Number of subjects: 515
Study: 28422968

Group type: EXPERIMENTAL
Intervention: Point of care (POC) device plus usual practice
Number of subjects: 13638

Group type: COMPARATOR
Intervention: Usual practice alone (control)
Number of subjects: 13638
Study: 26728913

Group type: EXPERIMENTAL
Intervention: Telephone-assisted intervention
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Web-assisted intervention
Number of subjects: 435

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 435
Study: 24934845

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including mailed reminder letter, free FIT with low-literacy instructions, automated telephone and text reminders, and personal telephone outreach.
Number of subjects: 450

Group type: COMPARATOR
Intervention: Usual care including computerized reminders, standing orders for medical assistants, and clinician feedback.
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Intervention group completion rates: 10.2% prior to due date, 39.6% within 2 weeks, 24.0% within 2 to 13 weeks, 8.4% between 13 and 26 weeks.
Number of subjects: 450
Study: 22672707

Group type: EXPERIMENTAL
Intervention: EX-DEF (exercise followed by fasting)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: EX-BAL (exercise followed by carbohydrate intake)
Number of subjects: 8

Group type: COMPARATOR
Intervention: CON (inactive control trial)
Number of subjects: 8
Study: 19067286

Group type: EXPERIMENTAL
Intervention: IV ibuprofen (10 mg/kg, 5 mg/kg, and 5 mg/kg over 3 days)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 16112120

Group type: EXPERIMENTAL
Intervention: Vegetable lipid intake >or=34.4 g/day
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Vitamin E intake >or=7.726 mg/day
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Higher serum HDL cholesterol concentration (for 10mg/dl increase)
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Age (for 1 year increase)
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Smoking (for 10 packs/year increase)
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Pulse pressure (for 5 mmHg increase)
Number of subjects: 1251
Study: 15472099

Group type: EXPERIMENTAL
Intervention: Early vasospasm (EVSP)
Number of subjects: 3478

Group type: EXPERIMENTAL
Intervention: Early vasospasm (EVSP) severity
Number of subjects: 3478
Study: 11775393

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS; Pulmicort Respules)
Number of subjects: 670

Group type: COMPARATOR
Intervention: Conventional asthma therapy (CAT)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 670

Group type: COMPARATOR
Intervention: CAT
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: BIS and CAT
Number of subjects: 670
Study: 9690497

Group type: EXPERIMENTAL
Intervention: Radial artery (RA) utilization in CABG
Number of subjects: 138

Group type: COMPARATOR
Intervention: CABG without radial artery (RA)
Number of subjects: 138
Study: 8352699

Group type: EXPERIMENTAL
Intervention: Lovastatin (20-40 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3669200

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (PTFE) grafts
Number of subjects: 105

Group type: COMPARATOR
Intervention: Human umbilical vein grafts
Number of subjects: 105

Group type: COMPARATOR
Intervention: Comparison of PTFE and umbilical vein grafts
Number of subjects: 105
Study: 31759183

Group type: EXPERIMENTAL
Intervention: MGO Manuka Honey microemulsion eye cream applied to one eye overnight for 3 months
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: MGO Manuka Honey microemulsion eye cream
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control eye (no treatment)
Number of subjects: 53
Study: 29738271

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous Moderate-Intensity Exercise (CMIE)
Number of subjects: 8
Study: 25740268

Group type: EXPERIMENTAL
Intervention: Pradigastat 40 mg with a single dose of Levora‐28®
Number of subjects: 24

Group type: COMPARATOR
Intervention: Levora‐28® alone
Number of subjects: 24
Study: 24122191

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBOT) administered within 24 h to 48 h of burn injury
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no HBOT)
Number of subjects: 17
Study: 20352374

Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study: 18984264

Group type: EXPERIMENTAL
Intervention: Oral montelukast for 8 weeks in addition to oral prednisolone for 14 days and budenoside nasal spray for 8 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Oral prednisolone for 14 days and budenoside nasal spray for 8 weeks (Control)
Number of subjects: 38
Study: 15465071

Group type: EXPERIMENTAL
Intervention: GAD patients (preanxiolytic treatment)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Anxiolytic-treated GAD patients
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: GAD patients after treatment
Number of subjects: 202

Group type: COMPARATOR
Intervention: CD patients
Number of subjects: 202

Group type: COMPARATOR
Intervention: KT patients
Number of subjects: 202
Study: 11465435

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion with intravenous injection of erythropoietin 600 lU/kg after each blood predonation
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion without erythropoietin
Number of subjects: 78

Group type: COMPARATOR
Intervention: Homologous transfusion (control group)
Number of subjects: 78
Study: 9509446

Group type: EXPERIMENTAL
Intervention: Haemodialysis for 3 hours started after contrast medium administration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 30
Study: 8044451

Group type: EXPERIMENTAL
Intervention: Tiagabine (32 mg during open phase, 24 mg during double-blind phase)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 22
Study: 3056807

Group type: EXPERIMENTAL
Intervention: Biosynthetic human proinsulin (0.025, 0.05, 0.1 units/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biosynthetic human insulin (0.025, 0.05, 0.1 units/kg)
Number of subjects: 0
Study: 15848568

Group type: EXPERIMENTAL
Intervention: Basiliximab added to cyclosporine microemulsion and mycophenolate mofetil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cyclosporine microemulsion and mycophenolate mofetil without basiliximab
Number of subjects: 90
Study: 30328970

Group type: EXPERIMENTAL
Intervention: 1,000 mg mangosteen pericarp per day for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo per day for 24 weeks
Number of subjects: 0
Study: 28502528

Group type: EXPERIMENTAL
Intervention: alpha‐methyl‐paratyrosine (AMPT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy Control (HC)
Number of subjects: 40
Study: 25412759

Group type: EXPERIMENTAL
Intervention: Interprofessional virtual patient educational activity
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study: 24189367

Group type: EXPERIMENTAL
Intervention: CYD‐TDV
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 21493761

Group type: EXPERIMENTAL
Intervention: Low birth weight group
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study: 19553647

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation omitted
Number of subjects: 498

Group type: COMPARATOR
Intervention: Historical controls received prophylactic cranial irradiation
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: All patients (498 total)
Number of subjects: 498
Study: 17040484

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) chewing gum, 5 mg, 2 pieces, twice a day for 3 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo gum (CHX-free), same usage instructions as CHX group
Number of subjects: 31
Study: 15248205

Group type: EXPERIMENTAL
Intervention: Disease Activity Score (DAS) in the UMCN cohort
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: DAS28 in the COBRA cohort
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Standard deviation (SD) of the mean interval DAS in the UMCN cohort
Number of subjects: 337
Study: 10789609

Group type: EXPERIMENTAL
Intervention: Typical American diet high in saturated fat (37% energy from fat)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: American Heart Association Step 1 diet (30% energy from fat)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Macadamia nut-based monounsaturated fat diet (37% energy from fat)
Number of subjects: 30
Study: 9073005

Group type: EXPERIMENTAL
Intervention: Deep inhalation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Forceful and deep inhalation
Number of subjects: 100
Study: 8145398

Group type: EXPERIMENTAL
Intervention: UF-021 (0.12%)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Timolol (0.5%)
Number of subjects: 158
Study: 3519053

Group type: EXPERIMENTAL
Intervention: Hexabrix 250
Number of subjects: 89

Group type: COMPARATOR
Intervention: Hexabrix 320
Number of subjects: 89
Study: 25904673

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 10
Study: 24578289

Group type: EXPERIMENTAL
Intervention: Interactive computer program
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care with provider‐based counseling
Number of subjects: 150
Study: 22251105

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 200

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 200
Study: 21268369

Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 0
Study: 18412958

Group type: EXPERIMENTAL
Intervention: Daily acid regurgitation
Number of subjects: 4902

Group type: COMPARATOR
Intervention: Less frequent or no symptoms of gastro-oesophageal reflux
Number of subjects: 4902
Study: 16215331

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (OxyContin)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 11940291

Group type: EXPERIMENTAL
Intervention: Low dose recombinant tissue-type plasminogen activator (rt-PA) thrombolysis
Number of subjects: 261

Group type: COMPARATOR
Intervention: Primary coronary stenting
Number of subjects: 261
Study: 9450711

Group type: EXPERIMENTAL
Intervention: Positive trials
Number of subjects: 43708

Group type: COMPARATOR
Intervention: Negative trials
Number of subjects: 43708

Group type: EXPERIMENTAL
Intervention: Trials with significant results favoring any arm
Number of subjects: 43708

Group type: COMPARATOR
Intervention: Trials with nonsignificant results
Number of subjects: 43708
Study: 7650092

Group type: EXPERIMENTAL
Intervention: MPH (Methylphenidate); specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experimenter-absent condition; control group is normal controls
Number of subjects: 0
Study: 2719748

Group type: EXPERIMENTAL
Intervention: 200 micrograms of muroctasin (H group)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 100 micrograms of muroctasin (L group)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Untreated control (C group)
Number of subjects: 131
Study: 1174902

Group type: EXPERIMENTAL
Intervention: Aminocaproic acid 3 g taken six-hourly during menstruation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as women not receiving aminocaproic acid)
Number of subjects: 56
Study: 31618495

Group type: EXPERIMENTAL
Intervention: Oral taurine for 12 weeks
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 404
Study: 30789931

Group type: EXPERIMENTAL
Intervention: CROS/BiCROS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: soft-band BAHA
Number of subjects: 0

Group type: COMPARATOR
Intervention: CROS/BiCROS and soft-band BAHA
Number of subjects: 0
Study: 29141522

Group type: EXPERIMENTAL
Intervention: WALANT
Number of subjects: 40

Group type: COMPARATOR
Intervention: LA/tourniquet
Number of subjects: 40
Study: 25203506

Group type: EXPERIMENTAL
Intervention: 8% CHO maltodextrin (WASH)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Noncaloric artificial sweetener (PLA)
Number of subjects: 12
Study: 23681295

Group type: EXPERIMENTAL
Intervention: Observation of an actor lifting an object
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifting an object with weight changes between 2 and 7 N
Number of subjects: 0
Study: 20722531

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) plus anorganic bovine bone matrix (ABM) with synthetic cell‐binding peptide P‐15
Number of subjects: 18

Group type: COMPARATOR
Intervention: Acellular dermal matrix (ADM) only
Number of subjects: 18
Study: 19930587

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 64)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (n = 65)
Number of subjects: 129
Study: 16527639

Group type: EXPERIMENTAL
Intervention: Removable appliance with palatal crib combined with high-pull chincup therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 12950425

Group type: EXPERIMENTAL
Intervention: Symptomatic patients with gastro-oesophageal reflux disease or duodenal gastro-oesophageal reflux
Number of subjects: 38

Group type: COMPARATOR
Intervention: Asymptomatic controls
Number of subjects: 38
Study: 16687507

Group type: EXPERIMENTAL
Intervention: High trait reward sensitivity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low trait reward sensitivity
Number of subjects: 0
Study: 10364948

Group type: EXPERIMENTAL
Intervention: PIN stripping of the long saphenous vein (LSV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional stripping
Number of subjects: 80
Study: 8727845

Group type: EXPERIMENTAL
Intervention: Maternal education and maternal responsiveness
Number of subjects: 182

Group type: COMPARATOR
Intervention: Maternal education alone
Number of subjects: 182
Study: 1984898

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 623

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623
Study: 6851273

Group type: EXPERIMENTAL
Intervention: Metoprolol, 200 mg daily
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 27561310

Group type: EXPERIMENTAL
Intervention: PROMIS static short-form instruments
Number of subjects: 0
Study: 27013068

Group type: EXPERIMENTAL
Intervention: Fellow eye trabeculectomy
Number of subjects: 159

Group type: COMPARATOR
Intervention: Fellow eye surgery refusal
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Increased fellow eye preoperative intraocular pressure (IOP)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Study eye hypotony at 3 months postoperatively
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Argon suture lysis procedure
Number of subjects: 159
Study: 24508634

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 200 U
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 22608478

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no cataract surgery)
Number of subjects: 42
Study: 21128060

Group type: EXPERIMENTAL
Intervention: S-1 monotherapy (40 mg/m², orally twice daily, days 1-28, every 6 weeks)
Number of subjects: 153
Study: 17951625

Group type: EXPERIMENTAL
Intervention: SFC (salmeterol 50 microg/fluticasone 500 microg, twice daily)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study: 15871736

Group type: EXPERIMENTAL
Intervention: Lacto-vegetarian, vegan or Mediterranean diets
Number of subjects: 95

Group type: COMPARATOR
Intervention: Ordinary diet
Number of subjects: 95
Study: 12503832

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 10941382

Group type: EXPERIMENTAL
Intervention: Kapandji's intrafocal pinning (Group I)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Py's isoelastic pinning (Group II)
Number of subjects: 88
Study: 8599586

Group type: EXPERIMENTAL
Intervention: Zenith Premium alloy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Valiant PhD alloy
Number of subjects: 2
Study: 2801590

Group type: EXPERIMENTAL
Intervention: Liquid cow-milk-based formula containing 1.3 mumol Cu/L (n = 16)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Liquid cow-milk-based formula supplemented with 7.8 mumol Cu/L as Cu sulfate (n = 16)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Exclusively breast-fed infants
Number of subjects: 200
Study: 30125376

Group type: EXPERIMENTAL
Intervention: 250 mg/kg acetylcysteine over 12 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: 300 mg/kg acetylcysteine over 20 hours
Number of subjects: 100